The Federal Government began on Tuesday (11th) the SUS Sovereign Cloud program. This initiative involves a large transfer of national health data to internally located servers. The administration of these computers will be managed by the State, utilizing Serpro (Federal Data Processing Service), aiming to ensure digital sovereignty in the area.
In addition to ensuring greater accessibility to patient data for health institutions, the measure aims to reduce dependence on foreign technologies. Implementation will occur in distinct phases: the first phase will cover more than 230 million Brazilian and foreign citizens registered in the National Registry of SUS Users (CadSUS). Subsequently, the second stage will focus on the National Health Data Network (RNDS), which covers about 5 billion records. The final plan foresees the consolidation of over 450 integrated applications.
As informed by the Ministry of Health, the experience of Brazilian users accessing SUS digital services will remain unchanged, but with reinforced security guarantees, in compliance with the LGPD, and with data integration at the federal level. Minister Alexandre Padilha announced an initial contribution of R$ 18 million for this first phase, named Foundation, with the goal of completing the CadSUS migration by the end of 2027.
This action is aligned with the concept of digital governance. The government mentioned that nations such as China, Russia, and various European countries are undergoing similar processes, seeking internal control over public services, which are currently fully embedded in the digital environment.
A study conducted in 2025 by the Department of Geography of the Federal University of Paraná (UFPR) had highlighted the risks of keeping sensitive SUS data on foreign company platforms. Currently, the RNDS is hosted on Serpro MultiCloud, an infrastructure that uses services from large technology companies, such as Amazon Web Services (AWS). The proposed migration serves as a strategy to circumvent this technological dependence.
In another context of digital governance, the participation of Brazil in WAICO, the International Organization for Artificial Intelligence Cooperation, stands out. The 29 members of this organization work to find methods that increase the Global South's access to artificial intelligence development. Despite having national AI models, Brazil still depends on LLMs from foreign corporations, notably American ones like Google, OpenAI, and Anthropic, and there is still a long way to go to achieve independence in this sector.
During the event held in Brasília, the Federal Government presented data on the digitalization of SUS. Currently, the SUS Digital application registers more than 70 million downloads, and its professional version already has integration with 84% of municipalities in the country. The unification of this information promises to facilitate access for these professionals. Additionally, the ministry emphasizes the relevance of digitalization for offering services such as telemedicine, which saw growth last year. This service can also benefit from migration to fully national servers, allowing greater agility in cross-referencing data and information about specialized care and support networks.
A cohort study involving 55,394 patients established a link between the use of the third-generation atypical antipsychotic aripiprazole and a reduced risk of low blood sodium levels, known as hyponatremia.
According to the study data, the risk of developing hyponatremia when using aripiprazole was lower than when using the second-generation antipsychotic olanzapine. The adjusted odds ratio was determined to be 0.52.
The results of this scientific investigation were officially published in the journal JAMA Network Open.
Research published in the journal Nature Genetics revealed the existence of an immune cell subtype in the brain capable of helping to contain the damage related to Alzheimer's disease. To reach this conclusion, scientists examined over 830,000 cells from 1,607 donors, covering various age ranges and degrees of alteration associated with the pathology.
The study, conducted by the Icahn School of Medicine at Mount Sinai, demonstrated that these cells undergo modifications throughout the aging process and during the progression of Alzheimer's. A specific group of microglia, which constitutes the main cerebral immune defense, captured the researchers' attention.
Scientists analyzed myeloid-derived immune cells, which originate in the bone marrow and migrate to the nervous system. This cellular set included microglia and perivascular macrophages, both involved in modulating the immune response.
Cell samples were collected from the prefrontal cortex of the 1,607 participants. From this material, six subclasses were delineated, totaling 13 distinct subtypes.
This mapping allowed for the tracking of transformations in these populations both during aging and as Alzheimer's symptoms progressed. A population was observed that intensifies with the advancement of Alzheimer's, but whose data suggest that this microglial subtype does not contribute to the worsening of brain damage; on the contrary, it demonstrates an opposite behavior, beginning to phagocytose and eliminate harmful materials more effectively.
The team also identified a molecular pathway involving the proteins TREM2, MITF, and GPNMB, which is essential for maintaining microglia in this protective state. Tests conducted on human tissues and murine models confirmed that the observed benefits depend on TREM2-mediated signaling.
Donghoon Lee, Assistant Professor of Genetics and Genomic Sciences and Psychiatry at the Icahn School of Medicine at Mount Sinai and the lead author of the work, stated that the study offers 'the clearest view to date of how the brain's immune cells adapt during aging and Alzheimer's disease.' The findings help explain why genetic variations linked to the immune system, such as TREM2 and APOE, are correlated with an elevated risk of developing Alzheimer's.
Lee added that, 'by identifying the specific immune cells that appear to protect the brain and analyzing the molecular signals they depend on, we discovered new potential targets for therapies aimed at slowing the progression of Alzheimer's disease.' This discovery points to a new therapeutic approach that transcends amyloid protein plaques, focusing on strengthening the inherent immune defenses of the brain itself.
Swedish researchers have completed a national cohort study and concluded that in people suffering from Alzheimer's disease, taking modern anticoagulants to treat atrial fibrillation leads to a significantly slower decline in cognitive abilities.
According to the study results, patients taking these modern drugs demonstrate improvement in other clinical indicators, while the risk of serious bleeding remains unchanged.
This scientific work was published in the European Heart Journal.
